Abstract
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma. The primary goal of therapy is to reduce symptoms related to direct infiltration of the bone marrow and decrease monoclonal IgM-associated complications. Active agents in the management of WM can be broadly classified as rituximab-alkylator combination therapy, proteasome inhibitor-based therapy, and Bruton's tyrosine kinase inhibitor-based therapy. MYD88L265P and CXCR4 genetic status are pivotal for tailoring treatment options. Ibrutinib is a suitable treatment option for both treatment-naïve and relapsing WM patients. Recent advances in the intracellular B cell and cytokine signaling pathways have contributed to the development of novel therapeutic strategies. Current clinical trials are promising and may further advance WM-directed therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 146-157 |
Number of pages | 12 |
Journal | Acta Haematologica |
Volume | 144 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- Bendamustine
- Bruton's tyrosine kinase inhibitors
- Ibrutinib
- Proteasome inhibitor
- Rituximab
- Waldenström macroglobulinemia
ASJC Scopus subject areas
- Hematology